Today: 2 February 2026
Subscribe
Browse Category

NASDAQ:RARE News 30 December 2025 - 31 December 2025

Ultragenyx stock today: RARE steadies premarket after setrusumab Phase 3 miss, FDA gene-therapy filing in focus

Ultragenyx stock today: RARE steadies premarket after setrusumab Phase 3 miss, FDA gene-therapy filing in focus

NEW YORK, December 31, 2025, 09:15 ET — Premarket Ultragenyx Pharmaceutical (RARE.O) shares edged down 0.2% to $22.74 in premarket trading on Wednesday, after finishing Tuesday up 15.5% at $22.78. The stock’s 52-week range is $18.41 to $46.50. StockAnalysis The rare-disease drugmaker is trying to find its footing after a sharp two-day repricing driven by a late-stage clinical setback that…
31 December 2025
····
Ultragenyx stock sinks 42% after Phase 3 setrusumab miss; what RARE investors watch nextNEW YORK, December 29, 2025, 23:21 ET — Market closed

Ultragenyx stock sinks 42% after Phase 3 setrusumab miss; what RARE investors watch nextNEW YORK, December 29, 2025, 23:21 ET — Market closed

Ultragenyx Pharmaceutical Inc shares slid on Monday after the company said two late-stage studies of setrusumab for osteogenesis imperfecta missed their primary fracture-reduction goal, prompting plans for significant expense reductions. “We are surprised and disappointed by these results,” Chief Executive Emil Kakkis said. Shares last traded down 42.3% at $19.72 after the close, versus a prior close of $34.19, after…
30 December 2025
····

Stock Market Today

  • Exxon Mobil Q4 Beat Highlights Permian and Guyana Output, Valuation at Crossroads
    February 2, 2026, 1:48 PM EST. Exxon Mobil (XOM) posted better-than-expected Q4 2025 results, driven by record upstream production in the Permian Basin and Guyana, alongside notable cost savings. The stock gained 15.29% over the past month and delivered a 36.88% total return over the past year. Despite trading above the average analyst target price of $134.04 at $141.40, a valuation model from Helzur suggests the stock is 7.1% overvalued, with a fair value estimated at $132.00 per share. This assessment emphasizes Exxon's strong cash flow, disciplined capital allocation, and operational excellence without relying on high oil price assumptions. Risks remain from commodity price volatility and potential policy-driven decarbonization impacts on upstream and Low Carbon Solutions business units.
Go toTop